Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy

Journal of the American Academy of Dermatology

Volumn 54, Issue 6, 2006, Pages 1033-1038

  Tucker, Stephen B ^a   Polasek, Jerry W ^b   Perri, Anthony J ^c   Goldsmith, Elizabeth A ^d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; DATA ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT ASSESSMENT; PRIORITY JOURNAL; SAMPLE SIZE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; MALE; SKIN NEOPLASMS; TIME FACTORS;

EID: 33646509240     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.02.035     Document Type: Article

References (15)

1. Chen J.G., Fleischer A.B., Smith E.D., Kancler C., Goldman N.D., Williford P.M., et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg 27 (2001) 1035-1038
2. Wong C.S.M., Strange R.C., and Lear J.T. Basal cell carcinoma. BMJ 327 (2003) 794-798
3. Martinez J.C., and Otley C.C. The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc 76 (2001) 1253-1265
4. Physicians' Desk Reference. 59th ed. (2005), Thompson PDR, Montvale (NJ) p. 3035
5. Kim K.H., Yavel R.M., Gross V.L., and Brody N. Intralesional interferon α-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 30 (2004) 116-120
6. Greenway H.T., Cornell R.C., Tanner D.J., Peets E., Bordin G.M., and Nagi C. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15 (1986) 437-443
7. Cornell R.C., Greenway H.T., Tucker S.B., Edwards L., Ashworth S., Vance J.C., et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 23 (1990) 694-700
8. Rowe D.E., Carroll R.J., and Day Jr. C.L. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15 (1989) 315-328
9. Sexton M., Jones D.B., and Maloney M.E. Histologic pattern analysis of basal cell carcinoma. Study of a set of 1039 consecutive neoplasms. J Am Acad Dermatol 23 (1990) 1118-1126
10. Edwards L., Tucker S.B., Perednia D., Smiles K.A., Taylor E.L., Tanner D.J., et al. The effect of an intralesional sustained-released formulation of interferon alpha 2b on basal cell carcinomas. Arch Dermatol 126 (1990) 1029-1032
11. Thestrup-Pedersen K., Jacobsen I.E., and Frentz G. Intralesional interferon alpha 2b treatment of basal cell carcinoma. Acta Derm Venereol 70 (1990) 512-514
12. Boneschi V., Brambilla L., Chiappino G., Mozzanica N., and Finzi A.F. Intralesional alpha 2b recombinant interferon for basal cell carcinomas. Int J Dermatol 30 (1991) 220-224
13. Healsmith M.F., Berth-Jones J., Fletcher A., and Graham-Brown R.A. Treatment of basal cell carcinoma with intralesional interferon alpha 2b. J R Soc Med 84 (1991) 524-526
14. Chimenti S., Peris K., Di Cristofaro S., Fargnoli M.C., and Torlone G. Use of recombinant interferon alpha 2b in the treatment of basal cell carcinoma. Dermatology 190 (1995) 214-217
15. Tucker S.B. Interferon-alpha treatment of basal cell and squamous cell skin tumors. Cancer Bull 45 (1993) 270-274